From network pharmacology to experimental verification: Angelica sinensis and its key constituent β‑sitosterol exert anti‑liver cancer effects through the p53 signaling pathway

Liver cancer remains a major cause of cancer mortality and the limited benefit of existing therapies leaves a clear need for new therapeutic agents. Although Angelica sinensis (AS) shows broad antitumor potential, its mechanistic basis against liver cancer remains unclear. The present study revealed that AS reduced the viability, proliferation and migration of the HepG2 human liver cancer cell line. Network pharmacology pointed to several putative targets including insulin, peroxisome proliferator‑activated receptor γ, nuclear factor κB subunit 1, estrogen receptor 1 and albumin. By combining molecular docking, molecular dynamics simulation and Cell Counting Kit‑8 cell viability screening, β‑sitosterol (BS) was identified from the candidate compounds of AS for further study, based on its stable interactions with central targets and its strong antiproliferative activity against HepG2 cells in vitro. Mechanistic assays of BS revealed that its anti‑liver cancer effect was mediated through the p53 pathway. BS treatment increased the proportion of apoptotic cells, together with increased expression of the tumor suppressor protein p53 and the pro‑apoptotic proteins Bax and Caspase‑3, and reduced expression of the anti‑apoptotic protein Bcl‑2. Co‑treatment with pifithrin‑α hydrobromide, a p53 inhibitor, partly reduced the proportion of apoptotic cells and partly reversed these changes in protein expression, confirming a p53‑dependent mechanism. The present study clarified the mechanisms by which AS, and its active component BS, suppress the proliferation and migration of liver cancer cells and trigger apoptosis through the modulation of the p53 pathway. These results support AS and BS as promising leads for development of plant‑derived therapies against liver cancer.

Authors

Institutions

Publication Details

Journal
Molecular Medicine Reports
Published
2026-11-19
DOI
https://doi.org/10.3892/mmr.2026.14079
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From network pharmacology to experimental verification: Angelica sinensis and its key constituent β‑sitosterol exert anti‑liver cancer effects through the p53 signaling pathway

Fengmei Deng, Weitong Li, Yang Song, Ying Du et al.
Molecular Medicine Reports
Computational Drug Discovery Methods
article

From network pharmacology to experimental verification: Angelica sinensis and its key constituent β‑sitosterol exert anti‑liver cancer effects through the p53 signaling pathway

Fengmei Deng, Weitong Li, Yang Song, Ying Du, Yuting Fan, Bin Tang, Haotian Shen, Yuxin zhang, Li Cheng, Jinhui Wang
article en

Abstract

Liver cancer remains a major cause of cancer mortality and the limited benefit of existing therapies leaves a clear need for new therapeutic agents. Although Angelica sinensis (AS) shows broad antitumor potential, its mechanistic basis against liver cancer remains unclear. The present study revealed that AS reduced the viability, proliferation and migration of the HepG2 human liver cancer cell line. Network pharmacology pointed to several putative targets including insulin, peroxisome proliferator‑activated receptor γ, nuclear factor κB subunit 1, estrogen receptor 1 and albumin. By combining molecular docking, molecular dynamics simulation and Cell Counting Kit‑8 cell viability screening, β‑sitosterol (BS) was identified from the candidate compounds of AS for further study, based on its stable interactions with central targets and its strong antiproliferative activity against HepG2 cells in vitro. Mechanistic assays of BS revealed that its anti‑liver cancer effect was mediated through the p53 pathway. BS treatment increased the proportion of apoptotic cells, together with increased expression of the tumor suppressor protein p53 and the pro‑apoptotic proteins Bax and Caspase‑3, and reduced expression of the anti‑apoptotic protein Bcl‑2. Co‑treatment with pifithrin‑α hydrobromide, a p53 inhibitor, partly reduced the proportion of apoptotic cells and partly reversed these changes in protein expression, confirming a p53‑dependent mechanism. The present study clarified the mechanisms by which AS, and its active component BS, suppress the proliferation and migration of liver cancer cells and trigger apoptosis through the modulation of the p53 pathway. These results support AS and BS as promising leads for development of plant‑derived therapies against liver cancer.

Molecular Medicine ReportsVol. 35(1)
Harbin Medical University (CN), Chengdu Medical College (CN), First Affiliated Hospital of Chengdu Medical College (CN)
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon